Coave Therapeutics will be attending the Cell & Gene Meeting on the Med, organized by Alliance for Regenerative Medicine, taking place April 15–17 in Rome, Italy.
Our CEO, Rodolphe Clerval, will speak on the panel “Science Slam: Ocular Indications” on April 15 and deliver a company presentation later that day.
We look forward to sharing how Coave is enhancing the precision, safety, efficacy and manufacturability of genetic medicines for neurodegenerative and ocular diseases, using its proprietary ALIGATERTM platform.
Panelists include:
Amit Rakhit, MD, MBA (BlueRock Therapeutics)
Laura Koivusalo (StemSight)
Andy Ramelmeier (Adverum Biotechnologies)

More info here: https://lnkd.in/eBfPV_SU
#CellandGeneMeeting #GeneTherapy #Ophthalmology #Biotech #GeneticMedicines

Lolita Petit, our CSO at Coave Therapeutics, is attending this year's Bio-Neuroscience Global Summit.
Please reach out if you would like to schedule a meeting!

🗓️ Bio-Neuroscience 2025
📍 Amsterdam, NL
📅 25th-27th February, 2025
📌 https://lnkd.in/eJcBGZ2t


Dr. Julien SPATAZZA, our Senior Director of Discovery & Preclinical Developmental, will be presenting a poster at the Drug Delivery to the Brain: Emerging Modalities Conference.

Poster Number: 1552
Poster Title: The Advanced Ligand Conjugation (ALIGATERTM) Platform Chemically Redirects AAV Vectors Towards TfR1 Receptor

🗓️ Drug Delivery to the Brain: Emerging Modalities
📍 Keystone Resort, Keystone, CO, US
📅 18th February, 2025 7.30PM
📌 https://lnkd.in/dHQQ4mhd
#Coavetx #AAV #BioNeuroscience #keystonesymposia

We are hiring a Principal Scientist/Associate Director to lead one of our cutting-edge capsid discovery programs, driving innovation in gene therapy for muscle, neuromuscular, and eye diseases. If you're ready to make an impact, let’s connect!

Today marks an exciting milestone for Coave as we successfully raise €32M ($33M) in a Series A financing, co-led by Novo Holdings A/S and Bpifrance (InnoBio strategy), with participation from The Invus Group, UI Investissement, and our existing investors.

This funding will support the advancement of our proprietary ALIGATERTM (Advanced Vectors-Ligand Conjugates) platform, designed to enhance precision, manufacturability, and safety in genetic medicines, and to drive our lead programs, targeting CNS, neuromuscular, and eye diseases, toward clinical development.

We are grateful for the support of our investors and partners as we continue to pioneer a new era of targeted and safer genetic therapies.

See our press release here: https://lnkd.in/e-sJxF7w

#SeriesAFinancing #GeneTherapy #BiotechInnovation #GeneticMedicines #LifeSciences #Biotech

We are delighted to share that HORA-PDE6b, an investigational gene therapy developed by eyeDNA Therapeutics, has received FDA Rare Pediatric Disease Designation (RPDD). HORA-PDE6b has shown meaningful visual improvements and a strong safety profile in an ongoing Phase I/II trial.

PDE6b-related Retinitis Pigmentosa is a rare inherited retinal dystrophy affecting up to 3,000 people in the US and 4,000 in Europe. Symptoms typically begin in childhood and progress to blindness by midlife, with no approved treatments currently available.

This RPDD provides eligibility for a Priority Review Voucher upon marketing authorization.

Read more here: https://lnkd.in/eTAFiBTw

#GeneTherapy #RetinalDisease #RarePediatricDiseaseDesignation #RetinitisPigmentosa